Flexion Therapeutics (FLXN) Given a $39.00 Price Target by Wells Fargo & Co Analysts

Flexion Therapeutics (NASDAQ:FLXN) has been assigned a $39.00 target price by research analysts at Wells Fargo & Co in a research note issued on Sunday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Wells Fargo & Co’s price target suggests a potential upside of 136.94% from the company’s current price.

Several other brokerages also recently issued reports on FLXN. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. BidaskClub upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 15th. Finally, ValuEngine downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $36.20.

Shares of NASDAQ FLXN opened at $16.46 on Friday. The company has a market capitalization of $617.44 million, a PE ratio of -3.96 and a beta of 1.17. Flexion Therapeutics has a 52-week low of $13.36 and a 52-week high of $29.10. The company has a debt-to-equity ratio of 1.02, a quick ratio of 8.74 and a current ratio of 8.88.

Flexion Therapeutics (NASDAQ:FLXN) last issued its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.09. The firm had revenue of $6.99 million for the quarter, compared to the consensus estimate of $5.93 million. Flexion Therapeutics had a negative net margin of 1,346.87% and a negative return on equity of 88.21%. On average, research analysts anticipate that Flexion Therapeutics will post -4.64 earnings per share for the current year.

In related news, CFO David Arkowitz acquired 4,000 shares of the stock in a transaction that occurred on Friday, November 9th. The shares were bought at an average price of $16.56 per share, for a total transaction of $66,240.00. Following the completion of the transaction, the chief financial officer now directly owns 48,250 shares in the company, valued at $799,020. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael D. Clayman acquired 5,000 shares of the stock in a transaction that occurred on Friday, November 9th. The shares were bought at an average price of $17.10 per share, for a total transaction of $85,500.00. Following the transaction, the insider now owns 83,295 shares of the company’s stock, valued at $1,424,344.50. The disclosure for this purchase can be found here. 14.59% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Flexion Therapeutics by 1.1% during the third quarter. Vanguard Group Inc. now owns 1,619,112 shares of the specialty pharmaceutical company’s stock valued at $30,294,000 after purchasing an additional 18,323 shares during the period. Teachers Advisors LLC increased its holdings in Flexion Therapeutics by 27.5% during the third quarter. Teachers Advisors LLC now owns 91,180 shares of the specialty pharmaceutical company’s stock valued at $1,706,000 after buying an additional 19,694 shares during the last quarter. Macquarie Group Ltd. increased its holdings in Flexion Therapeutics by 10.6% during the third quarter. Macquarie Group Ltd. now owns 66,703 shares of the specialty pharmaceutical company’s stock valued at $1,248,000 after buying an additional 6,399 shares during the last quarter. MetLife Investment Advisors LLC increased its holdings in Flexion Therapeutics by 52.1% during the third quarter. MetLife Investment Advisors LLC now owns 23,602 shares of the specialty pharmaceutical company’s stock valued at $442,000 after buying an additional 8,084 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Flexion Therapeutics during the third quarter valued at approximately $23,768,000.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

See Also: How to Track your Portfolio in Google Finance

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit